Health Care Originals

ADAMM is a wearable device that monitors respiratory parameters — cough frequency, wheeze, activity, and breathing patterns — and feeds data into a mobile app. The system translates these signals into personalized recommendations for medication timing and lifestyle adjustments. HCO also deploys a clinical-trial version, ADAMM-RSM, to collect real-world evidence for research sponsors.

The firm functions as an operating company, not an investment manager. It develops and sells a respiratory care service directly to patients and clinical-trial sponsors. No fund structures, limited partners, or deployment figures are disclosed on its corporate website.

Co-Founders Sharon and Jared Samjitsingh lead the company. Sharon, who has lived with severe asthma since birth, drives the clinical and care-delivery vision. Jared's specific operational role is not detailed on the firm's website beyond his co-founder designation.

Nightingale is HCO's direct-to-patient virtual respiratory care service. Subscribers choose a 12-month care plan — Hover or Fly — that includes smart-device tracking, an onboarding session with a respiratory therapist, and monthly therapist or health-coach sessions. The service targets asthma and COPD patients seeking ongoing disease management.

Revenue comes from two disclosed channels: direct-to-consumer subscription plans for the Nightingale service, and ADAMM-RSM contracts with clinical-trial sponsors that require real-world respiratory monitoring data. No institutional investment partnerships or fund-management fees are mentioned publicly.